全文获取类型
收费全文 | 5414篇 |
免费 | 392篇 |
国内免费 | 9篇 |
专业分类
耳鼻咽喉 | 60篇 |
儿科学 | 214篇 |
妇产科学 | 170篇 |
基础医学 | 673篇 |
口腔科学 | 74篇 |
临床医学 | 822篇 |
内科学 | 955篇 |
皮肤病学 | 136篇 |
神经病学 | 462篇 |
特种医学 | 122篇 |
外科学 | 589篇 |
综合类 | 36篇 |
一般理论 | 5篇 |
预防医学 | 517篇 |
眼科学 | 156篇 |
药学 | 398篇 |
1篇 | |
中国医学 | 23篇 |
肿瘤学 | 402篇 |
出版年
2024年 | 15篇 |
2023年 | 74篇 |
2022年 | 100篇 |
2021年 | 212篇 |
2020年 | 124篇 |
2019年 | 184篇 |
2018年 | 220篇 |
2017年 | 156篇 |
2016年 | 173篇 |
2015年 | 162篇 |
2014年 | 200篇 |
2013年 | 296篇 |
2012年 | 421篇 |
2011年 | 474篇 |
2010年 | 217篇 |
2009年 | 251篇 |
2008年 | 366篇 |
2007年 | 423篇 |
2006年 | 332篇 |
2005年 | 336篇 |
2004年 | 264篇 |
2003年 | 272篇 |
2002年 | 223篇 |
2001年 | 33篇 |
2000年 | 20篇 |
1999年 | 32篇 |
1998年 | 35篇 |
1997年 | 22篇 |
1996年 | 23篇 |
1995年 | 17篇 |
1994年 | 13篇 |
1993年 | 11篇 |
1992年 | 5篇 |
1991年 | 10篇 |
1990年 | 5篇 |
1989年 | 23篇 |
1988年 | 6篇 |
1987年 | 2篇 |
1986年 | 2篇 |
1985年 | 5篇 |
1984年 | 10篇 |
1983年 | 4篇 |
1982年 | 7篇 |
1981年 | 5篇 |
1980年 | 7篇 |
1979年 | 4篇 |
1978年 | 2篇 |
1977年 | 3篇 |
1976年 | 2篇 |
1968年 | 3篇 |
排序方式: 共有5815条查询结果,搜索用时 15 毫秒
91.
Janne Pleidrup Andersen Liselotte R. Norup Tina S. Dalgaard Lisa Rothwell Pete Kaiser Anders Permin 《Avian pathology》2013,42(3):276-282
In chickens, the nematode Ascaridia galli is found with prevalences of up to 100% causing economic losses to farmers. No avian nematode vaccines have yet been developed and detailed knowledge about the chicken immune response towards A. galli is therefore of great importance. The objective of this study was to evaluate the induction of protective immune responses to A. galli soluble antigen by different immunization routes. Chickens were immunized with a crude extract of A. galli via an oral or intra-muscular route using cholera toxin B subunit as adjuvant and subsequently challenged with A. galli. Only chickens immunized via the intra-muscular route developed a specific A. galli antibody response. Frequencies of γδ T cells in spleen were higher 7 days after the first immunization in both groups but only significantly so in the intra-muscularly immunized group. In addition, systemic immunization had an effect on both Th1 and Th2 cytokines in caecal tonsils and Meckel's diverticulum. Thus both humoral and cellular immune responses are inducible by soluble A. galli antigen, but in this study no protection against the parasite was achieved. 相似文献
92.
Simon G. Danby Ph.D. Tareq AlEnezi M.D. Amani Sultan M.D. Tina Lavender Ph.D. RM R.G.N. John Chittock B.Sc. Kirsty Brown B.Sc. Michael J. Cork Ph.D. F.R.C.P. 《Pediatric dermatology》2013,30(1):42-50
Natural oils are advocated and used throughout the world as part of neonatal skin care, but there is an absence of evidence to support this practice. The goal of the current study was to ascertain the effect of olive oil and sunflower seed oil on the biophysical properties of the skin. Nineteen adult volunteers with and without a history of atopic dermatitis were recruited into two randomized forearm‐controlled mechanistic studies. The first cohort applied six drops of olive oil to one forearm twice daily for 5 weeks. The second cohort applied six drops of olive oil to one forearm and six drops of sunflower seed oil to the other twice daily for 4 weeks. The effect of the treatments was evaluated by determining stratum corneum integrity and cohesion, intercorneocyte cohesion, moisturization, skin‐surface pH, and erythema. Topical application of olive oil for 4 weeks caused a significant reduction in stratum corneum integrity and induced mild erythema in volunteers with and without a history of atopic dermatitis. Sunflower seed oil preserved stratum corneum integrity, did not cause erythema, and improved hydration in the same volunteers. In contrast to sunflower seed oil, topical treatment with olive oil significantly damages the skin barrier, and therefore has the potential to promote the development of, and exacerbate existing, atopic dermatitis. The use of olive oil for the treatment of dry skin and infant massage should therefore be discouraged. These findings challenge the unfounded belief that all natural oils are beneficial for the skin and highlight the need for further research. 相似文献
93.
Iris Schrijver Nazneen Aziz Daniel H. Farkas Manohar Furtado Andrea Ferreira Gonzalez Timothy C. Greiner Wayne W. Grody Tina Hambuch Lisa Kalman Jeffrey A. Kant Roger D. Klein Debra G.B. Leonard Ira M. Lubin Rong Mao Narasimhan Nagan Victoria M. Pratt Mark E. Sobel Karl V. Voelkerding Jane S. Gibson 《The Journal of molecular diagnostics : JMD》2012,14(6):525-540
94.
95.
96.
Roy P Bonello L de Labriolle A Okabe T Pinto Slottow TL Steinberg DH Torguson R Smith K Xue Z Satler LF Kent KM Suddath WO Pichard AD Waksman R 《The American journal of cardiology》2008,102(3):292-297
Multiple studies comparing sirolimus-eluting stents (SES) and paclitaxel-eluting stents (PES) in patients with coronary artery disease have been performed. Despite these comparisons, it remains uncertain whether a differential in long-term efficacy and safety exists. Unselected patients treated exclusively with 1 drug-eluting stent type were enrolled in the Registry Experience at the Washington Hospital Center with Drug-Eluting Stents. There were 2,099 patients (3,766 lesions) treated with SES and 1,079 patients (1,850 lesions) treated with PES. Patients were followed at 30 days, 1 year, and 2 years for the clinical endpoints of death, myocardial infarction, target vessel revascularization, and definite and definite/probable stent thrombosis. Patients in the SES group had more dyslipidemia, history of congestive heart failure, and ostial lesions; patients treated with PES had more previous coronary artery bypass surgery, unstable angina, and type C lesions. At 2 years, unadjusted major adverse cardiac events (MACE) (22.6% vs 21.1%, p = 0.3) and target vessel revascularization (13.3% vs 11.2%, p = 0.1) were comparable. The incidence of definite stent thrombosis was higher in the SES group (1.8% vs 0.9%, p = 0.05) driven by early events. Similar results were seen after adjustment for baseline differences: MACE (hazard ratio 1.1, 95% confidence interval [CI] 0.9 to 1.3, p = 0.5), definite stent thrombosis (hazard ratio 2.3, 95% CI 1.0 to 5.2, p = 0.05), and target vessel revascularization (hazard ratio 1.1, 95% CI 0.9 to 1.4, p = 0.4). The incidence and rate of late stent thrombosis (>30 days) were similar (0.7% vs 0.5%, p = 0.4 and 0.24%/year, both groups, respectively). In conclusion, no major differential in long-term safety or efficacy was detected between SES and PES; both stent types were efficacious in reducing revascularization but were limited by a small continual increase in late stent thrombosis. 相似文献
97.
Steinberg DH Shah P Kinnaird T Pinto Slottow TL Roy PK Okabe T Bonello L de Labriolle A Smith KA Torguson R Xue Z Suddath WO Kent KM Satler LF Pichard AD Lindsay J Waksman R 《The American journal of cardiology》2008,102(2):160-164
For patients undergoing elective percutaneous coronary intervention (PCI), procedural anticoagulation with bivalirudin was previously shown to significantly reduce bleeding complications at the cost of a modest increase in ischemic events compared with unfractionated heparin (UFH) and glycoprotein IIb/IIIa inhibitors (GPIs). However, the excess bleeding in patients treated with UFH and GPIs may have been caused by excessively high UFH doses and increased activated clotting times. This study sought to determine the bleeding risk of targeted low-dose UFH with GPIs compared with bivalirudin in patients undergoing elective PCI. Of 1,205 patients undergoing elective PCI, 602 underwent PCI with adjunctive UFH and GPIs with the UFH dose targeted to an activated clotting time of approximately 250 seconds, and 603 patients matched for baseline characteristics underwent PCI with bivalirudin. Outcomes were analyzed for major bleeding (hematocrit decrease >15%, gastrointestinal bleed, or major hematoma) and 6-month major adverse cardiac events (death, myocardial infarction, and target-lesion revascularization). The maximum activated clotting time achieved was 261.7 +/- 61.6 seconds in the UFH/GPI group and 355.4 +/- 66.6 in the bivalirudin group (p <0.001). In-hospital major bleeding rates were similar between groups (1.8% UFH/GPI vs 1.7% bivalirudin; p = 0.83), as were transfusion requirements (1.2% UFH/GPI vs 0.5% bivalirudin; p = 0.61). The 6-month major adverse cardiac event rate was also similar between groups (9.5% UFH/GPI vs 9.0% bivalirudin; p = 0.81). In conclusion, there were no significant differences in major bleeding and 6-month major adverse cardiac events for patients undergoing elective PCI treated with targeted low-dose UFH and GPIs compared with those treated with bivalirudin. 相似文献
98.
99.
100.
Basil Miles Schwartz David Dalal Robin Horst Sara Scoville Elizabeth Adams Dawn Beaulieu Dawn Slaughter James C. Higginbotham Tina Vaezi Michael Choksi Yash 《Digestive diseases and sciences》2022,67(2):639-645
Digestive Diseases and Sciences - While the pathogenesis of inflammatory bowel disease (IBD) is incompletely understood, disruption of epithelial integrity is suspected to play a prominent role in... 相似文献